NOORUDDIN SHAIK. A Critical Review of Cinqair (Reslizumab) in the Treatment of Severe Asthma Patients. Future Journal of Pharmaceuticals and Health Sciences, [S. l.], v. 3, n. 2, p. 126–133, 2023. DOI: 10.26452/fjphs.v3i2.442. Disponível em: https://pharmasprings.com/fjphs/article/view/442. Acesso em: 16 nov. 2024.